Donepezil: A meta-analysis of individual patient data from randomized controlled trials in the treatment of patients with mild to moderate Alzheimer's disease.

被引：0
|
作者：
Pratt, RD
Wilcock, GK
Evans, JG
Birks, J
Whitehead, A
Perdomo, CA
机构：
[1] Eisai Inc, Teaneck, NJ USA
[2] Univ Bristol, Frenchay Hosp, Bristol, Avon, England
[3] Univ Oxford, Oxford, England
[4] Univ Reading, Reading, Berks, England
来源：
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY | 2001年 / 49卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
P14
引用
收藏
页码：S19 / S20
页数：2
相关论文
共 50 条
  • [1] Donepezil: A meta-analysis of individual patient data from randomized controlled trials in the treatment of patients with mild to moderate Alzheimer's disease.
    Perdomo, C
    Wilcock, GK
    Whitehead, A
    Evans, JG
    Birks, J
    Pratt, RD
    [J]. JOURNAL OF GENERAL INTERNAL MEDICINE, 2003, 18 : 197 - 197
  • [2] Donepezil: A meta-analysis of individual patient data from randomized controlled trials in the treatment of patients with mild to moderate Alzheimer's disease
    Wilcock, GK
    Whitehead, A
    Evans, JG
    Birks, J
    Perdomo, C
    Pratt, RD
    [J]. NEUROLOGY, 2001, 56 (08) : A339 - A339
  • [3] Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials
    Whitehead, A
    Perdomo, C
    Pratt, RD
    Birks, J
    Wilcock, GK
    Evans, JG
    [J]. INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2004, 19 (07) : 624 - 633
  • [4] Bapineuzumab for mild to moderate Alzheimer’s disease: a meta-analysis of randomized controlled trials
    Abdelrahman Ibrahim Abushouk
    Ahmed Elmaraezy
    Amro Aglan
    Reham Salama
    Samar Fouda
    Rana Fouda
    Ammar M. AlSafadi
    [J]. BMC Neurology, 17
  • [5] Bapineuzumab for mild to moderate Alzheimer's disease: a meta-analysis of randomized controlled trials
    Abushouk, Abdelrahman Ibrahim
    Elmaraezy, Ahmed
    Aglan, Amro
    Salama, Reham
    Fouda, Samar
    Fouda, Rana
    AlSafadi, Ammar M.
    [J]. BMC NEUROLOGY, 2017, 17
  • [6] Personalized Prediction of Alzheimer's Disease and Its Treatment Effects by Donepezil: An Individual Participant Data Meta-Analysis of Eight Randomized Controlled Trials
    Yoshida, Kazufumi
    Seo, Michael
    Luo, Yan
    Sahker, Ethan
    Cipriani, Andrea
    Leucht, Stefan
    Iwatsubo, Takeshi
    Efthimiou, Orestis
    Furukawa, Toshiaki A.
    [J]. JOURNAL OF ALZHEIMERS DISEASE, 2022, 89 (04) : 1143 - 1157
  • [7] Cerebrolysin in Mild-to-Moderate Alzheimer's Disease: A Meta-Analysis of Randomized Controlled Clinical Trials
    Gauthier, Serge
    Proano, Jefferson Voltaire
    Jia, Jianping
    Froelich, Lutz
    Vester, Johannes Christophe
    Doppler, Edith
    [J]. DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2015, 39 (5-6) : 332 - 347
  • [8] Donepezil in Mild Alzheimer's Disease: Meta-Analysis of Patient Cohort with Mild Dementia
    Murthy, Anita K.
    Goldman, Robert
    Zhang, Richard
    Sun, Yijun
    [J]. AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2008, 16 (03): : A112 - A112
  • [9] Meta-Analysis of Randomized Controlled Trials on the Efficacy and Safety of Donepezil, Galantamine, Rivastigmine, and Memantine for the Treatment of Alzheimer's Disease
    Li, Dan-Dan
    Zhang, Ya-Hong
    Zhang, Wei
    Zhao, Pu
    [J]. FRONTIERS IN NEUROSCIENCE, 2019, 13
  • [10] Monotherapy Is Good Enough for Patients with Mild-to-Moderate Alzheimer's Disease: A Network Meta-analysis of 76 Randomized Controlled Trials
    Tsoi, Kelvin K. F.
    Chan, Joyce Y. C.
    Chan, Felix C. H.
    Hirai, Hoyee W.
    Kwok, Timothy C. Y.
    Wong, Samuel Y. S.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 (01) : 121 - 130
12345